No abstract

Background: Alzheimer’s disease (AD) is characterized by a deposition of β-amyloid peptide and the neurofibrillary tangles of tau protein. Resveratrol is a neuroprotective agent, acting in the prevention of redox impairment, and could reduce neuronal damage in patients with AD. Objectives: Systematic review and meta-analysis about the effects of resveratrol supplementation on cognitive and functional performance in patients with AD. Methods: Databases were searched for primary studies that reported cognitive and functional performance based on ADAS-cog, ADCS-ADL or MMSE instruments in AD patients treated with resveratrol. Primary studies published up to May 2021 and without language and publication date restrictions were included. The measure of effect of the meta-analysis was presented as weighted mean difference (WMD). decrease in ADAS-cog scores [WMD: -3.69 points], and significant increases in ADCS-ADL [WMD: 5.65 points] and MMSE scores [WMD: 2.03 points] in the resveratrol intervention group, when compared to the placebo group. Conclusions: Resveratrol supplementation may result in improving cognitive and functional performance in AD patients.